FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991316167> ?p ?o ?g. }

• W1991316167 endingPage "861" @default.
• W1991316167 startingPage "855" @default.
• W1991316167 abstract "Airway hyperresponsiveness (AHR) to pharmacologic stimuli and sputum eosinophils might be useful in the individual adjustment of long-term asthma management. However, it is not clear whether inhaled glucocorticosteroids (GCSs) provide greater protection against specific surrogate markers of airways inflammation than other means. In addition, detailed longitudinal assessment of changes in airway response with inhaled GCSs has never been carried out.We compared changes in AHR to inhaled methacholine and adenosine 5'-monophosphate (AMP) after budesonide treatment in a randomized, double-blind, placebo-controlled, crossover study of patients with mild-to-moderate asthma. Subsequently, we undertook a separate study to examine the time course of the changes in AHR in more detail and the changes in sputum cell counts in relation to budesonide treatment.In the phase 1 of the study, patients undertook bronchial provocation studies with increasing doubling concentrations of methacholine (0.06 to 16 mg/mL) and AMP (3.125 to 800 mg/mL) before and after budesonide 0.8 mg/daily for 3 weeks. The bronchial responses to the inhaled agonists were expressed as the provocative concentration causing a 20% decline in FEV(1) (PC(20)). In phase 2 of the study, patients attended the laboratory on 12 separate occasions to investigate changes in PC(20) methacholine, PC(20) AMP, and sputum cell counts before, during, and after withdrawal of therapy with inhaled budesonide 0.8 mg/daily for 6 weeks.Budesonide treatment for 3 weeks significantly attenuated the constrictor response by 0.8 +/- 0.3 doubling doses for methacholine and by 2.6 +/- 0.5 doubling doses for AMP. These changes were significantly different from each other (P =.003). Significant variation in PC(20) methacholine (P <.05) value, PC(20) AMP (P <.001) value, percentage of sputum eosinophils (P <.001), and percentage of sputum epithelial cells (P <.001) were observed throughout the longitudinal assessment of changes in airway response to budesonide. Compared with the other surrogate markers, PC(20) AMP appears to be useful in promptly detecting early inflammatory changes of the asthmatic airways; a significant change of 1.6 +/- 0.3, 2.2 +/- 0.3, and 2.8 +/- 0.3 doubling doses of PC(20) AMP was observed at 1, 4, and 6 weeks, respectively, in the course of budesonide treatment.The present findings underline the exquisite selectivity of diverse surrogate markers of airway inflammation in response to inhaled budesonide. When compared with that to the other markers, AHR to inhaled AMP is an early and sensitive indicator of the beneficial anti-inflammatory effects of topical GCSs." @default.
• W1991316167 created "2016-06-24" @default.
• W1991316167 creator A5009340562 @default.
• W1991316167 creator A5015237596 @default.
• W1991316167 creator A5024052581 @default.
• W1991316167 creator A5053603161 @default.
• W1991316167 creator A5055474003 @default.
• W1991316167 creator A5055766018 @default.
• W1991316167 creator A5082522328 @default.
• W1991316167 creator A5089020623 @default.
• W1991316167 date "2002-12-01" @default.
• W1991316167 modified "2023-10-16" @default.
• W1991316167 title "Changes in sputum counts and airway hyperresponsiveness after budesonide: Monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation" @default.
• W1991316167 cites W1891391790 @default.
• W1991316167 cites W1919677047 @default.
• W1991316167 cites W1966070406 @default.
• W1991316167 cites W1978306928 @default.
• W1991316167 cites W1980648588 @default.
• W1991316167 cites W1986764494 @default.
• W1991316167 cites W1998782208 @default.
• W1991316167 cites W2004841456 @default.
• W1991316167 cites W2010262399 @default.
• W1991316167 cites W2014775105 @default.
• W1991316167 cites W2025058125 @default.
• W1991316167 cites W2031867711 @default.
• W1991316167 cites W2036948573 @default.
• W1991316167 cites W2049900497 @default.
• W1991316167 cites W2060234975 @default.
• W1991316167 cites W2072173344 @default.
• W1991316167 cites W2074435841 @default.
• W1991316167 cites W2101211836 @default.
• W1991316167 cites W2106811010 @default.
• W1991316167 cites W2109548522 @default.
• W1991316167 cites W2127158617 @default.
• W1991316167 cites W2139606678 @default.
• W1991316167 cites W2139961805 @default.
• W1991316167 cites W2144886265 @default.
• W1991316167 cites W2149742688 @default.
• W1991316167 cites W2151743411 @default.
• W1991316167 cites W2160220254 @default.
• W1991316167 cites W2167235805 @default.
• W1991316167 cites W2339711360 @default.
• W1991316167 doi "https://doi.org/10.1067/mai.2002.130050" @default.
• W1991316167 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12464950" @default.
• W1991316167 hasPublicationYear "2002" @default.
• W1991316167 type Work @default.
• W1991316167 sameAs 1991316167 @default.
• W1991316167 citedByCount "58" @default.
• W1991316167 countsByYear W19913161672012 @default.
• W1991316167 countsByYear W19913161672014 @default.
• W1991316167 countsByYear W19913161672015 @default.
• W1991316167 countsByYear W19913161672016 @default.
• W1991316167 countsByYear W19913161672017 @default.
• W1991316167 countsByYear W19913161672018 @default.
• W1991316167 countsByYear W19913161672019 @default.
• W1991316167 countsByYear W19913161672020 @default.
• W1991316167 countsByYear W19913161672021 @default.
• W1991316167 crossrefType "journal-article" @default.
• W1991316167 hasAuthorship W1991316167A5009340562 @default.
• W1991316167 hasAuthorship W1991316167A5015237596 @default.
• W1991316167 hasAuthorship W1991316167A5024052581 @default.
• W1991316167 hasAuthorship W1991316167A5053603161 @default.
• W1991316167 hasAuthorship W1991316167A5055474003 @default.
• W1991316167 hasAuthorship W1991316167A5055766018 @default.
• W1991316167 hasAuthorship W1991316167A5082522328 @default.
• W1991316167 hasAuthorship W1991316167A5089020623 @default.
• W1991316167 hasBestOaLocation W19913161671 @default.
• W1991316167 hasConcept C105922876 @default.
• W1991316167 hasConcept C110586980 @default.
• W1991316167 hasConcept C126322002 @default.
• W1991316167 hasConcept C142724271 @default.
• W1991316167 hasConcept C203014093 @default.
• W1991316167 hasConcept C204787440 @default.
• W1991316167 hasConcept C27081682 @default.
• W1991316167 hasConcept C2776042228 @default.
• W1991316167 hasConcept C2776136866 @default.
• W1991316167 hasConcept C2776178081 @default.
• W1991316167 hasConcept C2776238763 @default.
• W1991316167 hasConcept C2776301714 @default.
• W1991316167 hasConcept C2776954882 @default.
• W1991316167 hasConcept C2777714996 @default.
• W1991316167 hasConcept C2781069245 @default.
• W1991316167 hasConcept C2781260171 @default.
• W1991316167 hasConcept C42219234 @default.
• W1991316167 hasConcept C71924100 @default.
• W1991316167 hasConcept C90924648 @default.
• W1991316167 hasConceptScore W1991316167C105922876 @default.
• W1991316167 hasConceptScore W1991316167C110586980 @default.
• W1991316167 hasConceptScore W1991316167C126322002 @default.
• W1991316167 hasConceptScore W1991316167C142724271 @default.
• W1991316167 hasConceptScore W1991316167C203014093 @default.
• W1991316167 hasConceptScore W1991316167C204787440 @default.
• W1991316167 hasConceptScore W1991316167C27081682 @default.
• W1991316167 hasConceptScore W1991316167C2776042228 @default.
• W1991316167 hasConceptScore W1991316167C2776136866 @default.
• W1991316167 hasConceptScore W1991316167C2776178081 @default.
• W1991316167 hasConceptScore W1991316167C2776238763 @default.
• W1991316167 hasConceptScore W1991316167C2776301714 @default.

• next